FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083271211> ?p ?o ?g. }

• W2083271211 endingPage "531" @default.
• W2083271211 startingPage "525" @default.
• W2083271211 abstract "Alzheimer's disease (AD) is believed to be initiated by the accumulation of neurotoxic forms of Aβ peptide within the brain. AD patients show reduction of cerebral blood flow (CBF), the extent of the reduction correlating with the impairment of cognition. There is evidence that cerebral hypoperfusion precedes and may even trigger the onset of dementia in AD. Cerebral hypoperfusion impairs neuronal function, reduces the clearance of Aβ peptide and other toxic metabolites from the brain, and upregulates Aβ production. Studies in animal models of AD have shown the reduction in CBF to be more than would be expected for the reduction in neuronal metabolic activity. Aβ may contribute to the reduction in CBF in AD, as both Aβ1–40 and Aβ1–42 induce cerebrovascular dysfunction. Aβ1–40 acts directly on cerebral arteries to cause cerebral smooth muscle cell contraction. Aβ1–42 causes increased neuronal production and release of endothelin-1 (ET-1), a potent vasoconstrictor, and upregulation of endothelin-converting enzyme-2 (ECE-2), the enzyme which cleaves ET-1 from its inactive precursor. ET-1 and ECE-2 are also elevated in AD, making it likely that upregulation of the ECE-2–ET-1 axis by Aβ1–42 contributes to the chronic reduction of CBF in AD. At present, only a few symptomatic treatment options exist for AD. The involvement of ET-1 in the pathogenesis of endothelial dysfunction associated with elevated Aβ indicates the potential for endothelin receptor antagonists in the treatment of AD. It has already been demonstrated that the endothelin receptor antagonist bosentan, preserves aortic and carotid endothelial function in Tg2576 mice, and our findings suggest that endothelin receptor antagonists may be beneficial in maintaining CBF in AD." @default.
• W2083271211 created "2016-06-24" @default.
• W2083271211 creator A5055225566 @default.
• W2083271211 creator A5056046668 @default.
• W2083271211 date "2011-06-01" @default.
• W2083271211 modified "2023-09-27" @default.
• W2083271211 title "Endothelin receptor antagonists: Potential in Alzheimer's disease" @default.
• W2083271211 cites W1496503766 @default.
• W2083271211 cites W1500754494 @default.
• W2083271211 cites W1525061277 @default.
• W2083271211 cites W1536538075 @default.
• W2083271211 cites W1541167019 @default.
• W2083271211 cites W1553957684 @default.
• W2083271211 cites W1594119953 @default.
• W2083271211 cites W1595634746 @default.
• W2083271211 cites W1637989849 @default.
• W2083271211 cites W1744830941 @default.
• W2083271211 cites W1830318005 @default.
• W2083271211 cites W1966144812 @default.
• W2083271211 cites W1969391013 @default.
• W2083271211 cites W1971422800 @default.
• W2083271211 cites W1971699320 @default.
• W2083271211 cites W1972850922 @default.
• W2083271211 cites W1975303418 @default.
• W2083271211 cites W1977513074 @default.
• W2083271211 cites W1977819697 @default.
• W2083271211 cites W1980748384 @default.
• W2083271211 cites W1981132320 @default.
• W2083271211 cites W1983324123 @default.
• W2083271211 cites W1984009511 @default.
• W2083271211 cites W1985592940 @default.
• W2083271211 cites W1985717693 @default.
• W2083271211 cites W1987192204 @default.
• W2083271211 cites W1990427131 @default.
• W2083271211 cites W1990752558 @default.
• W2083271211 cites W1991991142 @default.
• W2083271211 cites W1992583442 @default.
• W2083271211 cites W1992602428 @default.
• W2083271211 cites W1992989380 @default.
• W2083271211 cites W1993726204 @default.
• W2083271211 cites W1994210129 @default.
• W2083271211 cites W1994554610 @default.
• W2083271211 cites W1995329423 @default.
• W2083271211 cites W1997822484 @default.
• W2083271211 cites W1999061258 @default.
• W2083271211 cites W1999206064 @default.
• W2083271211 cites W2000523989 @default.
• W2083271211 cites W2000658130 @default.
• W2083271211 cites W2001210466 @default.
• W2083271211 cites W2004421347 @default.
• W2083271211 cites W2008580181 @default.
• W2083271211 cites W2008767130 @default.
• W2083271211 cites W2009468295 @default.
• W2083271211 cites W2011090923 @default.
• W2083271211 cites W2013395798 @default.
• W2083271211 cites W2014886338 @default.
• W2083271211 cites W2015458192 @default.
• W2083271211 cites W2016326896 @default.
• W2083271211 cites W2019042091 @default.
• W2083271211 cites W2019349431 @default.
• W2083271211 cites W2024246194 @default.
• W2083271211 cites W2028403300 @default.
• W2083271211 cites W2029294139 @default.
• W2083271211 cites W2030333049 @default.
• W2083271211 cites W2030667927 @default.
• W2083271211 cites W2031173074 @default.
• W2083271211 cites W2032157350 @default.
• W2083271211 cites W2033067082 @default.
• W2083271211 cites W2034236657 @default.
• W2083271211 cites W2034897558 @default.
• W2083271211 cites W2035268008 @default.
• W2083271211 cites W2035463674 @default.
• W2083271211 cites W2036661577 @default.
• W2083271211 cites W2036792490 @default.
• W2083271211 cites W2038738480 @default.
• W2083271211 cites W2039169280 @default.
• W2083271211 cites W2040402315 @default.
• W2083271211 cites W2040490831 @default.
• W2083271211 cites W2040721710 @default.
• W2083271211 cites W2040811659 @default.
• W2083271211 cites W2040836716 @default.
• W2083271211 cites W2041185392 @default.
• W2083271211 cites W2041851050 @default.
• W2083271211 cites W2045219086 @default.
• W2083271211 cites W2047418563 @default.
• W2083271211 cites W2052742260 @default.
• W2083271211 cites W2053861465 @default.
• W2083271211 cites W2054792850 @default.
• W2083271211 cites W2057042201 @default.
• W2083271211 cites W2057226832 @default.
• W2083271211 cites W2060319077 @default.
• W2083271211 cites W2061353398 @default.
• W2083271211 cites W2061520576 @default.
• W2083271211 cites W2063236931 @default.
• W2083271211 cites W2065535274 @default.
• W2083271211 cites W2070466215 @default.
• W2083271211 cites W2070701688 @default.
• W2083271211 cites W2072361983 @default.

• next